{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T16:02:34Z","timestamp":1789401754419,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":60,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"DOI":"10.1186\/s12902-026-02426-4","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:04:40Z","timestamp":1784221480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between atherogenic index of plasma and MASLD in patients with type 2 diabetes: a cross-sectional study"],"prefix":"10.1186","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8490-0767","authenticated-orcid":false,"given":"Aysun","family":"Seker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2557-3812","authenticated-orcid":false,"given":"Seydahmet","family":"Ak\u0131n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"2426_CR1","doi-asserted-by":"crossref","unstructured":"Cusi K, et al. Metabolic Dysfunction\u2013Associated Steatotic Liver Disease (MASLD) in people with diabetes: the need for screening and early intervention. A Consensus Report of the American Diabetes Association. Diabetes Care; 2025.","DOI":"10.2337\/dci24-0094"},{"key":"2426_CR2","doi-asserted-by":"crossref","unstructured":"Maito S, et al. Transitions in the nomenclatures for fatty liver disease. J Hepatol. 2024;82(4).","DOI":"10.1016\/j.jhep.2024.12.019"},{"issue":"Suppl","key":"2426_CR3","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2022.0365","volume":"29","author":"M Teng","year":"2022","unstructured":"Teng M, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2022;29(Suppl):S32\u201342.","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"2426_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/S2468-1253(22)00317-X","volume":"8","author":"J Quek","year":"2023","unstructured":"Quek J, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20\u201330.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"2426_CR5","doi-asserted-by":"publisher","first-page":"103043","DOI":"10.1016\/j.arcmed.2024.103043","volume":"55","author":"A-S Ehsan","year":"2024","unstructured":"Ehsan A-S, et al. Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries. Arch Med Res. 2024;55(6):103043\u2013103043.","journal-title":"Arch Med Res"},{"issue":"4","key":"2426_CR6","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","volume":"71","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis. J Hepatol. 2019;71(4):793\u2013801.","journal-title":"J Hepatol"},{"issue":"10","key":"2426_CR7","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.cell.2021.04.015","volume":"184","author":"R Loomba","year":"2021","unstructured":"Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell. 2021;184(10):2537\u201364.","journal-title":"Cell"},{"key":"2426_CR8","doi-asserted-by":"crossref","unstructured":"Tilg H, Adolph TE, Moschen AR. Multiple parallel hits hypothesis in NAFLD \u2013 revisited after a decade. Hepatology. 2020.","DOI":"10.1002\/hep.31518"},{"issue":"10","key":"2426_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.cgh.2009.05.033","volume":"7","author":"AG Shah","year":"2009","unstructured":"Shah AG, et al. Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Clin Gastroenterol Hepatol. 2009;7(10):1104\u201312.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2426_CR10","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","volume":"68","author":"E Vilar-Gomez","year":"2018","unstructured":"Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68(2):305\u201315.","journal-title":"J Hepatol"},{"key":"2426_CR11","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33.","journal-title":"BMC Gastroenterol"},{"issue":"7","key":"2426_CR12","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","volume":"42","author":"JH Lee","year":"2010","unstructured":"Lee JH, et al. Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease. Dig Liver Dis. 2010;42(7):503\u20138.","journal-title":"Dig Liver Dis"},{"key":"2426_CR13","doi-asserted-by":"crossref","unstructured":"Samimi S, et al. Atherogenic index of plasma is an independent predictor of metabolic-associated fatty liver disease in patients with type 2 diabetes. Eur J Med Res. 2022;27(1).","DOI":"10.1186\/s40001-022-00731-x"},{"issue":"9","key":"2426_CR14","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.3390\/biomedicines10092101","volume":"10","author":"A Ismaiel","year":"2022","unstructured":"Ismaiel A, et al. Atherogenic Index of Plasma in Non-Alcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis. Biomedicines. 2022;10(9):2101.","journal-title":"Biomedicines"},{"key":"2426_CR15","doi-asserted-by":"crossref","unstructured":"Liu J, et al. The atherogenic index of plasma: a novel factor more closely related to non-alcoholic fatty liver disease than other lipid parameters in adults. Front Nutr. 2022;9:954219.","DOI":"10.3389\/fnut.2022.954219"},{"key":"2426_CR16","doi-asserted-by":"publisher","first-page":"969783","DOI":"10.3389\/fendo.2022.969783","volume":"13","author":"K Li","year":"2022","unstructured":"Li K, et al. Association between the atherogenic index of plasma and new-onset non-alcoholic fatty liver disease in non-obese participants. Front Endocrinol (Lausanne). 2022;13:969783.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2426_CR17","first-page":"384","volume":"41","author":"A Wang","year":"2024","unstructured":"Wang A, et al. The association between atherogenic index of plasma and metabolic dysfunction-associated fatty liver disease as detected by FibroScan. Nutr Hosp. 2024;41(2):384\u201392.","journal-title":"Nutr Hosp"},{"issue":"4","key":"2426_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023;77(4):1335\u201347.","journal-title":"Hepatology"},{"issue":"9","key":"2426_CR19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","volume":"18","author":"G Targher","year":"2021","unstructured":"Targher G, et al. The complex link between NAFLD and type 2 diabetes mellitus - mechanisms and treatments. Nat Rev Gastroenterol Hepatol. 2021;18(9):599\u2013612.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"2426_CR20","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","volume":"41","author":"A Mantovani","year":"2018","unstructured":"Mantovani A, et al. Nonalcoholic Fatty Liver Disease and Risk of Incident Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2018;41(2):372\u201382.","journal-title":"Diabetes Care"},{"issue":"7","key":"2426_CR21","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1373\/clinchem.2004.033175","volume":"50","author":"M Dobi\u00e1sov\u00e1","year":"2004","unstructured":"Dobi\u00e1sov\u00e1 M. Atherogenic index of plasma [log(triglycerides\/HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 2004;50(7):1113\u20135.","journal-title":"Clin Chem"},{"issue":"4","key":"2426_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1089\/met.2008.0034","volume":"6","author":"LE Simental-Mend\u00eda","year":"2008","unstructured":"Simental-Mend\u00eda LE, Rodr\u00edguez-Mor\u00e1n M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008;6(4):299\u2013304.","journal-title":"Metab Syndr Relat Disord"},{"issue":"1","key":"2426_CR23","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12902-022-01172-7","volume":"22","author":"W Li","year":"2022","unstructured":"Li W, et al. Association between triglyceride-glucose index and nonalcoholic fatty liver disease in type 2 diabetes mellitus. BMC Endocr Disord. 2022;22(1):261.","journal-title":"BMC Endocr Disord"},{"issue":"3","key":"2426_CR24","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jhep.2024.04.031","volume":"81","author":"EASL-EASD-EASO Clinical","year":"2024","unstructured":"EASL-EASD-EASO Clinical. Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81(3):492\u2013542.","journal-title":"J Hepatol"},{"key":"2426_CR25","doi-asserted-by":"crossref","unstructured":"Amiama Roig C, et al. Prospective validation of the EASL-EASD algorithm for risk stratification in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes. Rev Esp Enferm Dig. 2025.","DOI":"10.17235\/reed.2025.11545\/2025"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-026-02426-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02426-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-026-02426-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:04:11Z","timestamp":1789398251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12902-026-02426-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1186\/s12902-026-02426-4","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"11 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local institutional ethics committee (Decision No: 2025\/010.99\/21\/25, Date: 30 October 2025). The study was conducted in accordance with the principles of the Declaration of Helsinki. The requirement for informed consent was waived due to the retrospective nature of the study.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"271"}}